Biomedical and Human Factors Requirements for a Manned Earth Orbiting Station

This report is the result of a study conducted by Republic Aviation Corporation in conjunction with Spacelabs, Inc.,in a team effort in which Republic Aviation Corporation was prime contractor. In order to determine the realistic engineering design requirements associated with the medical and human factors problems of a manned space station, an interdisciplinary team of personnel from the Research and Space Divisions was organized. This team included engineers, physicians, physiologists, psychologists, and physicists. Recognizing that the value of the study is dependent upon medical judgments as well as more quantifiable factors (such as design parameters) a group of highly qualified medical consultants participated in working sessions to determine which medical measurements are required to meet the objectives of the study. In addition, various Life Sciences personnel from NASA (Headquarters, Langley, MSC) participated in monthly review sessions. The organization, team members, consultants, and some of the part-time contributors are shown in Figure 1. This final report embodies contributions from all of these participants

Properties of the phi meson at high temperatures and densities

We calculate the spectral density of the phi meson in a hot bath of nucleons and pions using a general formalism relating self-energy to the forward scattering amplitude (FSA). In order to describe the low energy FSA, we use experimental data along with a background term. For the high energy FSA, a Regge parameterization is employed. We verify the resulting FSA using dispersion techniques. We find that the position of the peak of the spectral density is slightly shifted from its vacuum position and that its width is considerably increased. The width of the spectral density at a temperature of 150 MeV and at normal nuclear density is more than 90 MeV.Comment: 4 pages, 5 figures, Poster presented at Quark Matter 200

Supersensitive PSA-Monitored neoadjuvant hormone treatment of clinically localized prostate cancer: Effects on positive margins, tumor detection and epithelial cells in bone marrow

Objective: The present study was done to investigate the effects of supersensitive PSA-controlled inductive treatment on positive margins, detection of tumor and epithelial cells in bone marrow of 101 patients with untreated and clinically localized prostatic carcinoma (cT1-3N0M0). Methods: Hormonal treatment was given until PSA (DPD Immulite(R) third-generation assay) reached 0.3 ng/ml in only 1 case. Of the 101 patients, 82 had a measurable hypoic lesion on initial transrectal ultrasound. 84% of these became smaller, 7.5% remained unchanged and 8.5% increased. Of the 101 prostatectomy specimens, 20 (20%) were margin-positive. The incidence of affected margins was relatively high (35% from 55 patients) with cT3 tumors, but almost negligible (2% from 46 patients) in cT1-2 tumor. Our pathologists, despite their great experience in evaluating hormonally treated prostates (>500 cases) and using immunohistochemical staining, were unable to detect carcinoma in 15 (15%) specimens. Whereas only 2 (4%) of the 55 cT3 specimens were without detectable tumor, this incidence rised to 28% (13 of 46 prostates) in patients with cT1-2 tumors. Of the initial 29 patients with epithelial cells in bone marrow, only 4 (14%) remained positive after controlled induction and all of them had fewer cells than before. Conclusion: Endocrine induction controlled by a supersensitive PSA assay and continued until reaching PSA nadir is highly effective in clearing surgical margins and eliminating tumor cells from bone marrow. It seems to be clearly superior to the conventional 3 months of pretreatment at least in cT1-2 tumors in respect to surgical margins and detectability of tumor in the resected prostate. A definitive statement about the value of endocrine induction can only be given by prospective randomized studies, with optimal drugs, doses and treatment time. But the conventional 3 months of pretreatment are far from exploiting the possibilities of this therapeutic option

The Asymptotic Giant Branches of GCs: Selective Entry Only

The handful of available observations of AGB stars in Galactic Globular Clusters suggest that the GC AGB populations are dominated by cyanogen-weak stars. This contrasts strongly with the distributions in the RGB (and other) populations, which generally show a 50:50 bimodality in CN band strength. If it is true that the AGB populations show very different distributions then it presents a serious problem for low mass stellar evolution theory, since such a surface abundance change going from the RGB to AGB is not predicted by stellar models. However this is only a tentative conclusion, since it is based on very small AGB sample sizes. To test whether this problem really exists we have carried out an observational campaign specifically targeting AGB stars in GCs. We have obtained medium resolution spectra for about 250 AGB stars across 9 Galactic GCs using the multi-object spectrograph on the AAT (2df/AAOmega). We present some of the preliminary findings of the study for the second parameter trio of GCs: NGC 288, NGC 362 and NGC 1851. The results indeed show that there is a deficiency of stars with strong CN bands on the AGB. To confirm that this phenomenon is robust and not just confined to CN band strengths and their vagaries, we have made observations using FLAMES/VLT to measure elemental abundances for NGC 6752.We present some initial results from this study also. Our sodium abundance results show conclusively that only a subset of stars in GCs experience the AGB phase of evolution. This is the first direct, concrete confirmation of the phenomenon.Comment: 4 pages, to appear in conference proceedings of "Reading the book of globular clusters with the lens of stellar evolution", Rome, 26-28 November 201

Quantification of MUCIN 1, cell surface associated and MUCIN16, cell surface associated proteins in tears and conjunctival epithelial cells collected from postmenopausal women

Srinivasan, S., Heynen, M. L., Martell, E., Ritter, R., Jones, L., & Senchyna, M. (2013). Quantification of MUCIN 1, cell surface associated and MUCIN16, cell surface associated proteins in tears and conjunctival epithelial cells collected from postmenopausal women. Molecular Vision, 19, 970–979.Purpose: To quantify the expression of mucin 1, cell surface associated (MUC1) and mucin 16, cell surface associated (MUC16) proteins and messenger ribonucleic acid (mRNA) in a cohort of postmenopausal women (PMW), to explore the relationship between mucin expression, dry eye symptomology, and tear stability.Methods: Thirty-nine healthy PMW (>50 years of age) were enrolled in this study. No specific inclusion criteria were used to define dry eye; instead, a range of subjects were recruited based on responses to the Allergan Ocular Surface Disease Index (OSDI) questionnaire and tear stability measurements as assessed by non-invasive tear breakup time (NITBUT). Tears were collected from the inferior tear meniscus using a disposable glass capillary tube, and total RNA and total protein were isolated from conjunctival epithelial cells collected via impression cytology. Expression of membrane-bound and soluble MUC1 and MUC16 were quantified with western blotting, and expression of MUC1 and MUC16 mRNA was assessed with real-time PCR.Results: OSDI responses ranged from 0 to 60, and NITBUT ranged from 18.5 to 2.9 s. Only two statistically significant correlations were found: soluble MUC16 protein concentration and MUC16 mRNA expression with OSDI vision related (−0.47; p=0.01) and ocular symptom (0.39; p=0.02) subscores, respectively. Post hoc exploratory analysis on absolute expression values was performed on two subsets of subjects defined as asymptomatic (OSDI ≤6, n=12) and moderate to severe symptomatic (OSDI ≥20, n=12). The only significant difference between the two subgroups was a significant reduction in MUC16 mRNA expression found in the symptomatic dry eye group (1.52±1.19 versus 0.57±0.44; p=0.03).Conclusions: A broad exploration of mucin expression compared to either a sign (NITBUT) or symptoms of dry eye failed to reveal compelling evidence supporting a significant relationship, other than a potential association between MUC16 with specific symptoms. Furthermore, comparison of mucin protein and expression levels between the asymptomatic and moderate to severe symptomatic subgroups revealed only one significant difference, a reduction in MUC16 mRNA expression in the symptomatic subgroup.Funding for this study was provided by Alcon Research Ltd and the Natural Sciences and Engineering Research Council of Canada (NSERC)

Microcanonical treatment of black hole decay at the Large Hadron Collider

This study of corrections to the canonical picture of black hole decay in large extra dimensions examines the effects of back-reaction corrected and microcanonical emission at the LHC. We provide statistical interpretations of the different multiparticle number densities in terms of black hole decay to standard model particles. Provided new heavy particles of mass near the fundamental Planck scale are not discovered, differences between these corrections and thermal decay will be insignificant at the LHC.Comment: small additions and clarifications, format for J. Phys.

Mass Segregation in the Globular Cluster Palomar 5 and its Tidal Tails

We present the stellar main sequence luminosity function (LF) of the disrupted, low-mass, low-concentration globular cluster Palomar 5 and its well-defined tidal tails, which emanate from the cluster as a result of its tidal interaction with the Milky Way. The results of our deep (B ~ 24.5) wide-field photometry unequivocally indicate that preferentially fainter stars were removed from the cluster so that the LF of the cluster's main body exhibits a significant degree of flattening compared to other globular clusters. There is clear evidence of mass segregation, which is reflected in a radial variation of the LFs. The LF of the tidal tails is distinctly enhanced with faint, low-mass stars. Pal 5 exhibits a binary main sequence, and we estimate a photometric binary frequency of roughly 10%. Also the binaries show evidence of mass segregation with more massive binary systems being more strongly concentrated toward the cluster center.Comment: 14 pages, 12 figures, accepted for publication in the Astronomical Journa

Medical Imaging Utilization Trends in Radiation Oncology over the Past Decade

Purpose/Objective(s): We quantify the increase in use of pre-treatment imaging and verification imaging in radiation oncology over the past decade. We also quantify the trend towards hypofractionation, which has partially led to increased imaging. Materials/Methods: The pre-treatment and verification imaging data used are from a single, tertiary, university-affiliated cancer center. Pre-treatment imaging was defined as magnetic resonance imaging (MRI), positron emission tomography (PET) and four-dimensional computed tomography (4DCT). Verification imaging was defined as cone-beam computed tomography (CBCT). All treatment approved plans were included from 2012 to 2021. Data extraction was performed using custom scripts interfacing with the treatment planning system (TPS) and patient information system. All registered image-sets of planning CT images with either advanced pre-treatment advanced imaging or verification images in the TPS were included. Hypofractionation sub-analysis was performed according to plans above and below 4 Gy per fraction that received a combination of pre-treatment and verification imaging. Results: Between 2012 and 2021, a total of 42,214 plans were included. In 2021, MRI, PET, and 4DCT pre-treatment imaging modalities were used for 14%, 5%, and 3% of patients, respectively, which was an increase from 5%, 2%, and 0%, in 2012. In 2021, 55% of patients received CBCT for verification imaging compared to only 2% of patients in 2012. In the sub-analysis, cohort receiving greater than or equal to 4 Gy per fraction from 2012 to 2021, the percent of patients receiving one of MRI or PET for pre-treatment imaging and CBCT guidance for verification imaging increased from 1% to 22%. For the cohort receiving less than 4 Gy per fraction, there was an increase from 2012 to 2021 of 0% to 14% of patients receiving at least one of MRI or PET pretreatment imaging and CBCT for verification imaging. Table 1: Annual use of advanced pre-treatment, verification imaging, hypofractionation, and associated combination imaging shown. Entries indicate the percent (%) of patients per year with the imaging modality used in their treatment. Conclusion: An increase in the adoption of advanced medical imaging was observed in standard of care treatments over the past 10 years. Imaging utilization continues to increase as clinical trial evidence matures. Further analysis could focus on the gap between desired standard of care for patients and the current offerings as well as the increase in capital and human resource requirement for implementation of these advancements